Search
pirtobrutinib (Jaypirca)
Indications:
- chronic lymphocytic leukemia (CLL), including previously treated CLL [1]
Dosage:
- 200 mg PO QD
Adverse effects:
- fatigue (20%), diarrhea (17%), contusion (13%)
- neutropenia in 10%, anemia in 4%
- abdominal pain, dyspnea, constipation, pyrexia each < 1%
Mechanism of action:
- Bruton tyrosine kinase inhibitor (BTK inhibitor)
General
small inhibitory antineoplastic agent (ib drug)
Database Correlations
PUBCHEM cid=129269915
References
- Ingram I
Pirtobrutinib Makes Splash as New CLL Drug
Highly active in pretreated patients, even prior BTK inhibitor exposure,
with little toxicity.
MedPage Today March 8, 2021
https://www.medpagetoday.com/hematologyoncology/leukemia/91533
- Mato AR et al
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN):
A phase 1/2 study.
Lancet 2021, Mar 6;397(10277):892-901
PMID: 33676628
- Michot JM, Ribrag V.
Pirtobrutinib shows evidence to inaugurate a third generation of BTK inhibitors.
Lancet 2021. Mar 6;397(10277):855-857.
PMID: 33676615